Page 885 - Basic _ Clinical Pharmacology ( PDFDrive )

See footnote 4. Avoid elvitegravir/ cobicistat, etravirine, fosamprenavir, nevirapine, tipranavir. Avoid in severe hepatic insufficiency. The oral powder contains phenylalanine. See footnote 4. Avoid elvitegravir/ cobicistat and simeprevir. Avoid in patients with sulfa allergy. See footnote 4. Avoid concurrent fosamprenavir. Teratogenic in rats. Avoid concurrent neuropathic drugs (eg, stavudine, zalcitabine, isoniazid), ribavirin, or allopurinol. Chewable tablets contain Avoid

Comments Avoid alcohol. phenylalanine. nevirapine.

Characteristic Adverse Effects Rash, hypersensitivity reaction, nausea; possible increase in myocardial infarction Nausea, rash, myalgia, indirect hyperbilirubinemia, diarrhea, ↑ liver enzymes, prolonged PR interval Diarrhea, headache, nausea, rash, hyperlipidemia, ↑ liver enzymes, ↑ serum amylase Rash, ↑ liver enzymes, head- ache, nausea, diarrhea Peripheral neuropathy, pan- creatitis, diarrhea. Insomnia, headache, hypersensitivity reaction, ↑ liver enzymes Neuropsychiatri

Administration Recommendation Test to rule out the presence of the HLA-B5701 allele prior to initiation of therapy. Take with food. Avoid concomitant antacids. Separate dosing acid- reducing agents by ≥10 h. Take with food. Separate dosing from ddI or antacids by ≥1 h. Take on an empty stomach. Separate dosing from antac- ids and polyvalent cations by ≥2 h. Take on an empty stomach, at bedtime. Take with food. Separate dos- ing from antacids by ≥2 h.

Currently available antiretroviral agents.
Recommended Adult Dosage 300 mg bid or 600 mg qd 400 mg qd or 300 mg qd with ritonavir 100 mg qd or cobicistat 150 mg qd; adjust dose in hepatic insufficiency Treatment-naïve: 800 mg qd with ritonavir 100 mg qd or cobicistat 150 mg qd Treatment-experienced: 600 mg bid with ritonavir 100 mg bid 400 mg tid Tablets, 400 mg qd or 200 mg bid 3 adjusted for weight Buffered powder, 250 mg bid 3 INSTI-naïve: 50 mg qd If co-administered with efavirenz, fosam- prenavir/ritonavir, tipranavir/ritonav

Class of Agent NRTI 1 PI 2 PI 2 NNRTI NRTI 1 INSTI NNRTI INSTI NRTI 1

TABLE 49–3 Agent Abacavir Atazanavir Darunavir Delavirdine Didanosine (ddI) Dolutegravir Efavirenz Elvitegravir Emtricitabine

871